Analysts Issue Forecasts for SLN FY2029 Earnings

Silence Therapeutics plc (NASDAQ:SLN) – HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Silence Therapeutics in a report released on Wednesday, January 29th. HC Wainwright analyst P. Trucchio forecasts that the company will earn $0.66 per share for the year. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Silence Therapeutics’ current full-year earnings is ($1.75) per share.

A number of other research firms also recently commented on SLN. Morgan Stanley reissued an “overweight” rating and set a $49.00 price objective on shares of Silence Therapeutics in a report on Tuesday, October 8th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Chardan Capital reissued a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Finally, William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Stock Performance

NASDAQ:SLN opened at $5.25 on Friday. The stock has a market capitalization of $157.12 million, a price-to-earnings ratio of -3.34 and a beta of 1.08. Silence Therapeutics has a 1 year low of $4.82 and a 1 year high of $27.72. The stock has a fifty day moving average price of $6.63 and a two-hundred day moving average price of $13.94.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors have recently modified their holdings of SLN. Janus Henderson Group PLC increased its stake in Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after acquiring an additional 268,250 shares during the last quarter. Millennium Management LLC boosted its stake in Silence Therapeutics by 91.2% during the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after acquiring an additional 373,523 shares during the last quarter. Eventide Asset Management LLC acquired a new position in Silence Therapeutics during the 3rd quarter worth $11,635,000. Ikarian Capital LLC increased its holdings in Silence Therapeutics by 15.9% in the third quarter. Ikarian Capital LLC now owns 587,343 shares of the company’s stock valued at $10,678,000 after buying an additional 80,678 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its holdings in shares of Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after acquiring an additional 208,029 shares during the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.